Skip to content

Savara SVRA Debt-to-equity

Debt-to-equity at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
19.9×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-1.5×
Innoviva, Inc. logo
Innoviva, Inc.INVA
0.2×
Theravance Biopharma logo
Theravance BiopharmaTBPH
0.1×-0.2×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
0.5×-0.2×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
-0.2×

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

Based on the most recent quarter.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's debt-to-equity?
Savara (SVRA) reported debt-to-equity of 0.2× in Q1 2026.
How has Savara's debt-to-equity changed year-over-year?
Savara's debt-to-equity decreased by 14.5% year-over-year, from 0.2× to 0.2×.
What is the long-term trend for Savara's debt-to-equity?
Over 5 years (2020 to 2025), Savara's debt-to-equity has grown at a -17.8% compound annual growth rate (CAGR), from 0.4× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.